Q3 FY26 PAT up 54%, interim dividend of Rs 75 per share declared

Revenue DeclinePat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹3203.00

prior close

₹3265.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.8%+0.4% vs sector

On the reaction day the stock moved 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.5

10m

+2.3

15m

+2.1

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4pendingpending-0.8+0.4

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q3 and nine-month FY26 results (Sep 30, 2026). Q3 revenue from operations was Rs 4,917 million versus Rs 4,754 million a year ago; PBT before exceptional items rose 22% to Rs 1,577 million and PAT rose 54% to Rs 1,167 million (EPS Rs 50.67). Nine-month revenue was Rs 14,017 million against Rs 14,176 million. Interim dividend of Rs 75 per share declared, record date Nov 5, 2026.

Likely market impact

Strong Q3 profit growth and a Rs 75 interim dividend may support the stock, though nine-month revenue was slightly lower than last year.